Medical Oncology

, Volume 28, Issue 4, pp 1589–1595

Partial trisomy 11, dup(11)(q23q13), as a defect characterizing lymphomas with Burkitt pathomorphology without MYC gene rearrangement

  • Barbara Pienkowska-Grela
  • Grzegorz Rymkiewicz
  • Beata Grygalewicz
  • Renata Woroniecka
  • Paulina Krawczyk
  • Katarzyna Czyz-Domanska
  • Jan Walewski
Original Paper

Abstract

Burkitt lymphoma (BL) is an aggressive non-Hodgkin lymphoma characterized by specific morphological and immunophenotypic features. The basic genetic feature of BL is the rearrangement of MYC gene, visible as t(8;14)(q24;q32) translocation or its variant. However, some lymphomas with characteristic BL morphology are nowadays diagnosed as B-cell lymphoma unclassifiable with features intermediate between DLBCL and BL (Inter-DLBCL/BL) for biological or clinical reasons. We present four lymphomas without the MYC rearrangement presented typical Burkitt morphology, FCM immunophenotype with some deviations when compared to a typical BL. The cases were finally diagnosed as Inter-DLBCL/BL. All of them presented a recurrent abnormality within the chromosome 11: dup(11)(q23q13). We suppose that the dup(11)(q23q13), in absence of the MYC gene rearrangement, is connected with borderline lymphomas with a morphology similar or identical to that of the Burkitt lymphoma. Identifying such an aberration may be helpful in the diagnostics of Inter-DLBCL/BL eventually forming a distinct subgroup of lymphomas.

Keywords

Non-Hodgkin’s lymphoma Burkitt morphology Chromosome aberrations FISH 

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Barbara Pienkowska-Grela
    • 1
  • Grzegorz Rymkiewicz
    • 2
  • Beata Grygalewicz
    • 1
  • Renata Woroniecka
    • 1
  • Paulina Krawczyk
    • 1
  • Katarzyna Czyz-Domanska
    • 3
  • Jan Walewski
    • 3
  1. 1.Cytogenetic LaboratoryMSCM Cancer Centre and InstituteWarsawPoland
  2. 2.Flow Cytometry LaboratoryMSCM Cancer Centre and InstituteWarsawPoland
  3. 3.Department of Lymphoprolipherative DiseaseMSCM Cancer Centre and InstituteWarsawPoland

Personalised recommendations